BEX2 is poor prognostic factor and required for cancer stemness in gastric cancer.

Humans Stomach Neoplasms / diagnosis Prognosis Cell Line, Tumor Oncogenes Nerve Tissue Proteins / metabolism
BEX2 CHRNB2 Gastric cancer

Journal

Biochemical and biophysical research communications
ISSN: 1090-2104
Titre abrégé: Biochem Biophys Res Commun
Pays: United States
ID NLM: 0372516

Informations de publication

Date de publication:
07 05 2023
Historique:
received: 27 02 2023
accepted: 09 03 2023
medline: 3 4 2023
pubmed: 19 3 2023
entrez: 18 3 2023
Statut: ppublish

Résumé

Gastric cancer is the fifth most common malignancy worldwide. However, targeted therapy for advanced gastric cancer is still limited. Here, we report BEX2 (Brain expressed X-linked 2) as a poor prognostic factor in two gastric cancer cohorts. BEX2 expression was increased in spheroid cells, and its knockdown decreased aldefluor activity and cisplatin resistance. BEX2 was found to upregulate CHRNB2 (Cholinergic Receptor Nicotinic Beta 2 Subunit) expression, a cancer stemness-related gene, in a transcriptional manner, and the knockdown of which also decreases aldefluor activity. Collectively, these data are suggestive of the role of BEX2 in the malignant process of gastric cancer, and as a promising therapeutic target.

Identifiants

DOI: 10.1016/j.bbrc.2023.03.025 PMID: 36933308
pubmed: 36933308
pii: S0006-291X(23)00302-9
doi: 10.1016/j.bbrc.2023.03.025
pii:
doi:

Substances chimiques

BEX2 protein, human 0
Nerve Tissue Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

59-67

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors have no conflicts of interest to disclose.

Auteurs

Akihiro Yasumoto (A)

Division of Cancer Stem Cell, Miyagi Cancer Center Research Institute, 47-1, Medeshima-Shiote, Natori, Miyagi, Japan; Division of Gastoroenterologic Surgery, Tohoku Medical and Pharmaceutical University, 1-15-1 Fukumuro, Miyaginoku, Sendai, Miyagi, 983-8536, Japan.

Haruna Fujimori (H)

Division of Cancer Stem Cell, Miyagi Cancer Center Research Institute, 47-1, Medeshima-Shiote, Natori, Miyagi, Japan.

Mai Mochizuki (M)

Division of Cancer Stem Cell, Miyagi Cancer Center Research Institute, 47-1, Medeshima-Shiote, Natori, Miyagi, Japan.

Rie Shibuya-Takahashi (R)

Division of Cancer Stem Cell, Miyagi Cancer Center Research Institute, 47-1, Medeshima-Shiote, Natori, Miyagi, Japan.

Mao Nakamura-Shima (M)

Division of Cancer Stem Cell, Miyagi Cancer Center Research Institute, 47-1, Medeshima-Shiote, Natori, Miyagi, Japan.

Norihisa Shindo (N)

Division of Molecular and Cellular Oncology, Miyagi Cancer Center Research Institute, 47-1, Medeshima-Shiote, Natori, Miyagi, Japan.

Kazunori Yamaguchi (K)

Division of Molecular and Cellular Oncology, Miyagi Cancer Center Research Institute, 47-1, Medeshima-Shiote, Natori, Miyagi, Japan.

Daisuke Fukushi (D)

Division of Gastroenterology, Tohoku Medical and Pharmaceutical University, 1-15-1 Fukumuro, Miyaginoku, Sendai, Miyagi, 983-8536, Japan.

Yuta Wakui (Y)

Department of Gastroenterology, Miyagi Cancer Center, 47-1, Medeshima-Shiote, Natori, Miyagi, Japan.

Takahiro Sugai (T)

Department of Gastroenterology, Miyagi Cancer Center, 47-1, Medeshima-Shiote, Natori, Miyagi, Japan.

Wataru Iwai (W)

Department of Gastroenterology, Miyagi Cancer Center, 47-1, Medeshima-Shiote, Natori, Miyagi, Japan.

Makoto Abue (M)

Department of Gastroenterology, Miyagi Cancer Center, 47-1, Medeshima-Shiote, Natori, Miyagi, Japan.

Ikuro Sato (I)

Department of Pathology, Miyagi Cancer Center, 47-1, Medeshima-Shiote, Natori, Miyagi, Japan.

Kennichi Satoh (K)

Division of Gastroenterology, Tohoku Medical and Pharmaceutical University, 1-15-1 Fukumuro, Miyaginoku, Sendai, Miyagi, 983-8536, Japan.

Yu Katayose (Y)

Division of Hepato-biliary-pancreatic Surgery, Tohoku Medical and Pharmaceutical University, 1-15-1 Fukumuro, Miyaginoku, Sendai, Miyagi, 983-8536, Japan.

Jun Yasuda (J)

Division of Molecular and Cellular Oncology, Miyagi Cancer Center Research Institute, 47-1, Medeshima-Shiote, Natori, Miyagi, Japan.

Chikashi Shibata (C)

Division of Gastoroenterologic Surgery, Tohoku Medical and Pharmaceutical University, 1-15-1 Fukumuro, Miyaginoku, Sendai, Miyagi, 983-8536, Japan.

Keiichi Tamai (K)

Division of Cancer Stem Cell, Miyagi Cancer Center Research Institute, 47-1, Medeshima-Shiote, Natori, Miyagi, Japan. Electronic address: tamaikeiichi@med.tohoku.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › BEX2 is poor prognostic factor and required...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Maladies de l'estomac › Tumeurs de l'estomac › BEX2 is poor prognostic factor and required...
questionsmedicales.fr › Diagnostic › Pronostic › BEX2 is poor prognostic factor and required...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › BEX2 is poor prognostic factor and required...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Génome › Composants de génome › Gènes › Gènes tumoraux › Oncogènes › BEX2 is poor prognostic factor and required...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines de tissu nerveux › BEX2 is poor prognostic factor and required...